Literature DB >> 16898171

European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders.

A Wiik1, R Cervera, M Haass, C Kallenberg, M Khamashta, P L Meroni, J-C Piette, R Schmitt, Y Shoenfeld.   

Abstract

The rational way to set a diagnosis and estimate a prognosis in rheumatology is to start by setting a tentative diagnosis and then follow a fixed scheme for laboratory testing, eg, by using an agreed algorithm. The use of order algorithms can be extended to post-test algorithms that will assist clinicians in approaching the right diagnosis and prognosis. New methods used in autoimmune serology do not deliver results that can be directly compared to those of older methods, and thus the new methods need to be thoroughly tested with sera from differential diagnostically relevant disease controls to set a clinically meaningful cut-off for positivity. Borderline positive results need to be treated with special care to avoid misuse. Early diagnosis is of great importance, and serological results can be very useful if used the right way. European efforts to secure rational diagnostic work-up in autoimmune rheumatic disease have led to a better dialogue between clinicians and laboratory scientists in several countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16898171     DOI: 10.1191/0961203306lu2322oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases.

Authors:  Nicola Bizzaro; Gabriella Morozzi
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

2.  An evaluation of autoimmune antibody testing patterns in a Canadian health region and an evaluation of a laboratory algorithm aimed at reducing unnecessary testing.

Authors:  Ada Man; Kam Shojania; Carmen Phoon; Jason Pal; Monika Hudoba de Badyn; David Pi; Diane Lacaille
Journal:  Clin Rheumatol       Date:  2013-01-06       Impact factor: 2.980

3.  A novel automated indirect immunofluorescence autoantibody evaluation.

Authors:  Shaye Kivity; Boris Gilburd; Nancy Agmon-Levin; Marina Garcia Carrasco; Yaron Tzafrir; Yael Sofer; Matilda Mandel; Thomas Buttner; Dirk Roggenbuck; Marco Matucci-Cerinic; Katalin Danko; Marcos López Hoyos; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2011-11-05       Impact factor: 2.980

Review 4.  [Laboratory diagnostics for early detection of rheumatic autoimmune diseases: a guide for the general practitioner].

Authors:  Georg Endler; Ulrike Demel; Ernst Forster; Andrea Griesmacher; Christin Hübner; Werner Klotz; Günter Steiner; W Wagner; Manfred Herold
Journal:  Wien Med Wochenschr       Date:  2012-08-14

Review 5.  [Diagnostic strategies for autoimmune rheumatic diseases].

Authors:  A S Wiik
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

6.  Routine use of Zenit RA, a novel chemiluminescent immunoanalyzer in autoimmune disease diagnosis.

Authors:  P Ghillani; L Dufat; S Himeur; M Miyara; Z Amoura; L Musset
Journal:  Auto Immun Highlights       Date:  2012-03-21

Review 7.  Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!

Authors:  Allan S Wiik; Nicola Bizzaro
Journal:  Auto Immun Highlights       Date:  2012-04-11

8.  The Reliability of a Novel Automated System for ANA Immunofluorescence Analysis in Daily Clinical Practice.

Authors:  Mohammed Alsuwaidi; Margit Dollinger; Martin Fleck; Boris Ehrenstein
Journal:  Int J Rheumatol       Date:  2016-05-09

9.  Pattern of antinuclear antibody and antiextractable nuclear antigen antibody test requisitions in Riyadh.

Authors:  Najla Ali Alghabban; Zahid Shakoor
Journal:  J Family Med Prim Care       Date:  2019-11-15

Review 10.  Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.

Authors:  Mandy Sowa; Rico Hiemann; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.